Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Eli Lilly stock was falling early Thursday even as the drugmaker posted first-quarter earnings that beat analysts’ ...

LLY has delivered impressive returns of 15% year-to-date, outperforming the S&P 500’s 5% decline during the same period. This ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...

Lilly’s stock has risen 14.8% so far this year compared ... including Mounjaro switches and supply constraints. Prices of most of Lilly’s products are declining in the United States.

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares ...